@Article{Chen2022,
journal="Folia Neuropathologica",
issn="1641-4640",
volume="60",
number="2",
year="2022",
title="Effects of miR-211-3p/RHBDD1 axis on cell proliferation, 
cell cycle progression, and epithelial-mesenchymal transition 
in glioma",
abstract="This study was designed to elucidate the relationship of miR-211-3p and rhomboid domain containing 1 (RHBDD1) in glioma. Here, we first observed that miR-211-3p directly targets the 3˘-UTR of RHBDD1 in glioma cells using dual-luciferase reporter assay, RNA immunoprecipitation (RIP) assay, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Western blot analysis. Pearson’s correlation analysis showed that miR-211-3p expression was negatively correlated with RHBDD1 expression in glioma tissues. CCK-8 assay, flow cytometry, and transwell assay were applied to assess cell proliferation, cell cycle distribution, migration, and invasion. The results showed that RHBDD1 knockdown inhibited cell proliferation, cell cycle G1/S transition, migration, and invasion in two glioma cell lines (U87 and LN-229). Knockdown of miR-211-3p obtained opposite results. Moreover, overexpression of RHBDD1 counteracted suppressive effects of miR-211-3p on glioma cells. Furthermore, decreased expression of CDK4, cyclin D1, N-cadherin, and vimentin as well as increased E-cadherin expression induced by miR-211-3p was reversed by RHBDD1 overexpression. Our results suggested that targeting miR-211-3p/RHBDD1 axis might be a novel effective therapeutic target for glioma treatment.",
author="Chen, Lei
and Wang, Xiangyi
and Zhu, Yude
and Liu, Fuquan
and Liu, Laixing
and Jiang, Ning",
pages="195--209",
doi="10.5114/fn.2022.118186",
url="http://dx.doi.org/10.5114/fn.2022.118186"
}